| Numéro de catalogue | HB015026 |
|---|
| Reactivité des espèces | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Espèce hôte | Human |
|---|
| Clonalité | Monoclonal |
|---|
| Isotype | IgG |
|---|
| ID de clone | YS110 |
|---|
| Activité biologique |
YS110 (0-250 ug/mL, 48 h) inhibits cell proliferation in a concentration dependent manner in NCI-H2452 cells [1]. YS110 (2 ug/mL, 24 h) leads to a significant increase in the proportion of G2/M phase and affects the expression of related proteins in NCI-H2452 cells [1]. YS110 (2 ug/mL, 6-24 h) elevates activating phosphorylation of p38 MAPK and ERK1/2 in NCI-H2452 cells [1]. YS110 (0-20 ug/mL, 48 h) inhibits cell growth of JMN cells in a dose-dependent manner [2]. YS110 (0-4 h) relies on the caveolin pathway to induce CD26 nuclear translocation in JMN cells [2]. YS110 (2 ug/mL, 3 h) significantly inhibits the mRNA and protein levels of POLR2A in JMN cells [2]. YS110 (10 ug/mL, 30 min) effectively inhibits MERS CoV S1-Fc specific binding to CD26 in JKT-hCD26WT cells [3]. YS110 (40 ug/mL, 30 min) significantly reduces MERS CoV infection rate in Huh-7 cells [3]. Cell Proliferation Assay [1] Cell Line: NCI-H2452 cells Concentration: 0, 0.1, 2, 10 and 250 ug/mL Incubation Time: 48 h Result: Inhibited the cell proliferation of NCI-H2452 cells. Cell Cycle Analysis [1] Cell Line: NCI-H2452 cells Concentration: 2 ug/mL Incubation Time: 24 h Result: Significantly increased the proportion of G2/M phase cells with an average increase of 8 %. Western Blot Analysis [1] Cell Line: NCI-H2452 cells Concentration: 2 ug/mL Incubation Time: 6 and 24 h Result: Significantly increased the level of p21, p-cdc2, p-cdc25C, p-p38 MAPK and p-ERK1/2. RT-PCR [2] Cell Line: JMN cells Concentration: 2 ug/mL Incubation Time: 3 h Result: Significantly reduced the mRNA level of POLR2A. Western Blot Analysis [2] Cell Line: JMN cells Concentration: 2 ug/mL Incubation Time: 3 h Result: Significantly reduced the protein level of POLR2A. YS110 (5 mg/kg or 5 ug, intratumoral injection or i.p., three times per week) can significantly inhibit tumor growth in NOG mice bearing JMN xenograft [1]. YS110 (8 mg/kg or 10 ug, intratumoral injection or i.p. |
| Système d'expression |
Mammalian cells |
| Cible |
TP103, Dipeptidyl peptidase IV, ADABP, Dipeptidyl peptidase 4, CD26, DPP4, Dipeptidyl peptidase IV soluble form, Dipeptidyl peptidase IV membrane form, DPP IV, ADCP2, Adenosine deaminase complexing protein 2, ADCP-2, T-cell activation antigen CD26 |
| Niveau d'endotoxines |
< 10 EU/mg |
| Pureté |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Numéro d'accès |
P27487 |
| Forme |
Liquid |
| Tampon de stockage |
0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
|
| Stabilité et stockage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | YS110 |
|---|
| Contexte | Dipeptidyl peptidase 4 (CD26/DPP4) is a ~88 kDa protein. Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. 1. Ikushima, H. et al. (2000) Proceedings of the National Academy of Sciences of the United States of America 97, 8439-44. PMID: 109000052. Durinx, C. et al. (2000) European journal of biochemistry 267, 5608-13. PMID: 109512213. Ginés, S. et al. (2002) The Biochemical journal 361, 203-9. PMID: 117723924. Ohnuma, K. et al. (2007) The Journal of biological chemistry 282, 10117-10131. PMID: 172872175. Aertgeerts, K. et al. (2004) Protein science : a publication of the Protein Society 13, 145-54. PMID: 14691230 |
|---|
| Reférences |
1. Hayashi M, et al. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell Int. 2016 Apr 30;16:35. [HB015026]
2. Yamada K, et al. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One. 2013 Apr 29;8(4):e62304. [HB015026]
3. Ohnuma K, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013 Dec;87(24):13892-9. [HB015026] |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
한국어
日本語
Español
Français
Русский
